Janssen Biotech, Inc.

Shalom Goldberg

Steven Jacobs

Karyn O'Neil

Donna Klein

Vadim Dudkin

Michael Diem

Linus Hyun

Rhys Salter

Rosa Cardoso

Tracy Spinka-Doms

Tricia Lin

Wei Zhang

John M Keith

Fengbin Song

Theresa Marie McDevitt

Michael J McCauley

Kristen Wiley

Mark L Anderson

Jinquan Luo

Sheng-Jiun Wu

Alexey Teplyakov

Ricardo Attar

Kristen Picha

Sheri Moores

Francois Gaudet

Yingzhe Li

Jill Marie Mooney

Alastair King

Glenn Mark Anderson

Ronan McDaid

Joseph Erhardt

Benjamin J Harman

Jennifer Nemeth-Seay

Galla Chandra Rao

Steven J Orcutt

Leopoldo Luistro

Neeraj Kohli

Rebecca Wissner

Steven Pomerantz

Karyn O'neil

Karyn O'NEIL

Macrocyclic chelators for chelation of alpha-emitting radiometal ions, such as actinium-225 are provided. Also provided are radiometal complexes containing an alpha-emitting radiometal ion bound to the macrocyclic chelator via coordinate bonding, and radioimmunoconjugates containing the radiometal complexes covalently linked to a targeting ligand, such as an antibody or antigen binding fragment thereof. The radioimmunoconjugates can be produced by click chemistry reactions. Methods of using the radiocomplexes and radioimmunoconjugates for selectively targeting neoplastic cells for radiotherapy and for treating neoplastic diseases and disorders are also described.

Macrocyclic chelators and methods of use thereof

Improved methods of radiolabeling antibodies using click chemistry are described. Also described are pharmaceutical compositions and uses related to the radiolabeled antibodies produced by the methods.

Radiolabeling of polypeptides

Engineered antibodies useful for site-specific conjugation by a transglutaminase are described. Also described are methods of site-specific conjugation of the antibodies, the site-specifically conjugated antibodies, and pharmaceutical compositions and uses related to the site-specifically conjugated antibodies.

Site-specific conjugation of glycosylated monoclonal antibodies with transglutaminase

Provided herein are methods for site-specific conjugation of glycan intact antibodies by a transglutaminase. According to particular embodiments, the reaction conditions are maintained or reduced to a low-ionic strength condition, which allows for efficient and fast conjugation without the need for antibody deglycosylation. Also described are pharmaceutical compositions and uses related to the conjugation method.

Methods for site specific conjugation of proteins containing glycosylated Fc domains

PSMA binding FN3 domains, their conjugates, isolated nucleotides encoding the molecules, vectors, host cells, and methods of making thereof are useful in the generation of therapeutic molecules and treatment and diagnosis of diseases and disorders.

Prostate specific membrane antigen binding fibronectin type iii domains

Disclosed herein are antibodies or antigen binding fragments thereof that bind prostate specific membrane antigen (PSMA), polynucleotides, vectors, host cells, radioconjugates, antibody drug conjugates and methods of treating cancer using the same.

Anti-PSMA antibodies and uses thereof

Cysteine engineered monospecific and bispecific EGFR and/or c-Met FN3 domain containing molecules comprising one or more free cysteine amino acids are prepared by mutagenizing a nucleic acid sequence of a parent molecule and replacing one or more amino acid residues by cysteine to encode the cysteine engineered FN3 domain containing monospecific or bispecific molecules; expressing the cysteine engineered FN3 domain containing molecules; and recovering the cysteine engineered FN3 domain containing molecule. Isolated cysteine engineered monospecific or bispecific FN3 domain containing molecules may be covalently attached to a detection label or a drug moiety and used therapeutically.

Cysteine engineered fibronectin type III domain binding molecules

Provided herein are isolated CD3&#xd7;PSMA-bispecific antigen-binding molecules or bispecific antigen-binding fragment thereof wherein a FN3 domain specifically binds human prostate specific membrane antigen (PSMA) and a second antigen-binding site immunospecifically binds CD3. Also described are fusion proteins and related polynucleotides capable of encoding the provided fusion proteins and, cells expressing the provided fusion proteins. In addition, methods of using the provided isolated CD3&#xd7;PSMA-bispecific antigen-binding molecules or bispecific antigen-binding fragment thereof are described.

Prostate specific membrane antigen (PSMA) bispecific binding agents and uses thereof

Prostate specific membrane antigen binding fibronectin type III domains

Growing community of inventors

Spring House, PA, United States of America

Shalom Goldberg